-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
BeiGene announced today that it will announce the results of multiple trials and the latest progress of its extensive clinical programs at the 2021 American Society of Clinical Oncology (ASCO) annual meeting
.
The current ASCO annual meeting will be held from June 4 to 8, 2021
Dr.
Wang to global research director Baiji China, said: "We are delighted to share the latest progress of the company in the field of malignant solid tumors and hematological tumors expanding pipeline of clinical products at this year's ASCO annual meeting, including Best Chak ® Associates has Fc innovation activity in the research of anti-drug antibodies ociperlimab TIGIT combination with other therapeutic agents variety, as well as ongoing new generation of BTK inhibitor Perrier Chak ® evaluation
.
we believe that these reports show demonstrates the integration of one of the Baiji China The scale, diversity and rapid development momentum of global clinical development projects hope to provide patients all over the world with more accessible and affordable innovative drugs
BeiGene designs diversified R&D projects for unmet patient needs
BeiGene's global research and development projects are extensive and diverse, including the evaluation of different mechanisms of action in common cancers, as well as the impact of various biomarkers, different histologies and various line of treatments on cancer treatment
.
The 2021 ASCO Annual Meeting will include the following highlights:
- One hundred ZeAn ® preliminary report for the second line treatment of advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC) 3 OF RATIONALE 302 patient clinical trial (NCT03430843) of
- One hundred ZeAn ® for the treatment of previously received treatment, locally advanced unresectable or metastatic microsatellite high stability (MSI-H) or a mismatch repair deficient (dMMR) 2 clinical trials in patients with solid tumors (NCT03736889) of Preliminary report
- Chak one hundred ® key two long-term follow-up of efficacy and safety results for the treatment of relapsed / refractory classical Hodgkin lymphoma (cHL) patients in clinical trials
Chak one hundred ® clinical benefit of the combination of innovative drugs in clinical trials aimed at improving the suppression of the immune checkpoint
Although immune checkpoint suppression has completely changed cancer treatment in the past decade, tumor immune escape caused by many mechanisms and factors is still very common, and the clinical benefits of patients are therefore limited
.
To further study and solve this problem, China Baiji assess the potential difference of the anti-PD-1 antibody Chak one hundred in an extensive clinical development program in ® 14 combined balance of medication, including chemotherapy, and targeted therapies other immunotherapies, clinical trial design details which combination of three drugs and the results will be announced at the ASCO annual meeting, were one hundred Chak ® joint research in anti-TIGIT antibody ociperlimab, one hundred Chak ® in combination with chemotherapy, And Baizian ® combined with the research anti-HER2 bispecific antibody zanidatamab (ZW25) authorized by Zymeworks
Continue on the new generation of BTK inhibitor Perrier Chak ® Assessment
Although BTK inhibitors have gradually become a standard treatment for B-cell malignancies, not all patients can achieve remission, and adverse events are the most common reason for discontinuation of treatment
.
Compared with the first generation of BTK inhibitor, Baiji China's new generation of BTK inhibitor Perrier Chak ® (erlotinib Zerbe) is designed to maximize the targeted market share, while avoiding off-target binding, thus improving efficacy and reducing Side effects
ASCO annual summary will be announced Perrier Chak ® for the treatment of previously treated with therapy and two clinical trials of patients with B-cell malignancies other BTK inhibitors are intolerant of (NCT04116437) latest data
.
At the 62nd Annual Meeting of the American Society of Hematology (ASH) in December 2020, BeiGene announced the results of the trial as of the previous data cut-off point in a poster presentation.
Baiji China recently announced Perrier Chak ® lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients with imatinib for the treatment of Bi Yibu adult relapsed or refractory (R / R) in chronic ALPINE 3 Qi The clinical trial obtained positive results in the interim analysis
.
Compared with ibrutinib, Baiyueze ® has achieved the objective response rate (ORR) superiority and effectiveness as assessed by the investigator; Baiyueze ® has achieved ORR non-inferiority after the researcher and the independent review committee (IRC) assessed
Baiji China 2021 annual ASCO Annual Meeting show report
| Report number # | Report title | Branch venue | time | Reporter |
| 4012 | RATIONALE 302: Randomized, Phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma. RATIONALE 302: one hundred ZeAn ® randomized controlled second-line chemotherapy for the treatment of advanced unresectable / metastatic esophageal squamous cell carcinoma Clinical Study 3
| Poster Discussion Session, Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Poster seminar, gastrointestinal cancer-gastroesophagus, pancreas and liver and gallbladder
| Friday, June 4th at 9 pm Beijing time (Friday, June 4th, US Eastern Time 9 am) | Peking University Cancer Hospital, Shen Lin, Doctor of Medicine
|
| 9102 | RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥65. RATIONALE 307: one hundred Chak ® in combination with chemotherapy for first-line treatment compare chemotherapy alone aged 65 and over with advanced squamous NSCLC patients
| Lung Cancer—Non-Small Cell Metastatic Lung cancer-non-small cell metastasis
| Friday, June 4th at 9 pm Beijing time (Friday, June 4th, US Eastern Time 9 am) | Doctor Wang Jie, Chinese Academy of Medical Sciences Peking Union Medical College
|
| 2569 | A Phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors. A one hundred ZeAn ® Phase 2 clinical study in patients with solid tumors mismatch repair defect as a single agent for the treatment of previously been treated locally advanced unresectable or metastatic microsatellite instability high / false
| Developmental Therapeutics—Immunotherapy Developmental therapy-immunotherapy
| Friday, June 4th at 9 pm Beijing time (Friday, June 4th, US Eastern Time 9 am) | Beijing Cancer Hospital, Doctor Li Jian
|
| 9069 | The Effects of Tislelizumab Treatment on the Health-Related Quality of Life of Non−Small Cell Lung Cancer Patients Who Progressed on a Prior Platinum-Containing Regimen. Chak one hundred ® impact on health related quality of life previously treated with platinum-containing drug treatment of patients with non-small cell lung cancer
| Lung Cancer—Non-Small Cell Metastatic Lung cancer-non-small cell metastasis
| Friday, June 4th at 9 pm Beijing time (Friday, June 4th, US Eastern Time 9 am) | Shanghai Pulmonary Hospital, Tongji University School of Medicine, Zhou Caicun, MD and PhD |
| 3109 | PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy. PARALLEL 303: A phase 2 randomized clinical study of maintenance treatment of inoperable locally advanced or metastatic gastric cancer patients with Baihuize® versus placebo in response to platinum-based first-line chemotherapy
| Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Development of therapies-molecularly targeted drugs and tumor biology
| Friday, June 4th at 9 pm Beijing time (Friday, June 4th, US Eastern Time 9 am) | Second University of Naples, Italy, Fortunato Ciardiello, MD, PhD
|
| 1087 | A Phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation. | Breast Cancer—Metastatic Breast cancer-metastatic
| Friday, June 4th at 9 pm Beijing time (Friday, June 4th, US Eastern Time 9 am) | Liaoning Cancer Hospital Research Institute, Dr. |
| 2583 | AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors. AdvanTIG-105: a monoclonal antibody anti-TIGIT ociperlimab (BGB-A1217) joint one hundred Chak ® clinical study of a dose for the treatment of patients with advanced solid tumors increments
| Developmental Therapeutics—Immunotherapy Developmental therapy-immunotherapy
| Friday, June 4th at 9 pm Beijing time (Friday, June 4th, US Eastern Time 9 am) | Sophia Frentzas, MD, Faculty of Medicine and Health Sciences, Monash University, Australia
|
| TPS5595 | AdvanTIG-202: A Phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer. AdvanTIG-202: a monoclonal antibody anti-TIGIT grind one hundred United ociperlimab ZeAn ® for the treatment of previously treated with Phase 2 clinical study of the treatment of recurrent or metastatic cervical cancer patients | Gynecologic Cancer
| Friday, June 4th at 9 pm Beijing time (Friday, June 4th, US Eastern Time 9 am) | Wu Lingying, Doctor of Medicine, Chinese Academy of Medical Sciences
|
| TPS4150 | AdvanTIG-203: A randomized Phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 AdvanTIG-203: TIGIT ociperlimab an antibody combined anti ZeAn one hundred ® comparison one hundred ZeAn ® randomized clinical study for two plus placebo in patients with esophageal squamous cell carcinoma Expression second line treatment of advanced or recurrent programmed death receptor 1
| Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Gastrointestinal cancer-gastroesophagus, pancreas, liver and gallbladder
| Friday, June 4th at 9 pm Beijing time (Friday, June 4th, US Eastern Time 9 am) | Sun Yat-sen University Cancer Center, Xu Ruihua, MD, PhD
|
| TPS9128 | AdvanTIG-302: Anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs pembrolizumab in programmed death ligand 1 selected, previously untreated, locally advanced, unresectable, or metastatic non-small cell lung cancer AdvanTIG-302: Anti-TIGIT antibody ociperlimab one hundred United ZeAn ® comparison for the treatment of locally advanced pembrolizumab selecting programmed death receptor 1, had not previously received treatment, unresectable or metastatic non-small cell lung cancer
| Lung Cancer—Non-Small Cell Metastatic Lung cancer-non-small cell metastasis
| Friday, June 4th at 9 pm Beijing time (Friday, June 4th, US Eastern Time 9 am) | AdventHealth Cancer Institute, Mark A. |
| TPS2656 | Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/ gastroesophageal junction adenocarcinoma: A Phase 1B/2 trial-in-progress Anti-HER2 bispecific antibodies zanidatamab combination chemotherapy with or without one hundred Chak ® for the first-line treatment of advanced HER2-positive breast cancer or gastric / gastroesophageal 1B / 2 clinical trial in patients with adenocarcinoma connection
| Developmental Therapeutics—Immunotherapy Developmental therapy-immunotherapy
| Friday, June 4th at 9 pm Beijing time (Friday, June 4th, US Eastern Time 9 am) | Seoul National University Hospital, South Korea, Keun Wook Lee MD, PhD |
| e19506 | Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib Preliminary results of a Phase 2 clinical study of zanubrutinib for the treatment of patients with B-cell malignancies who were previously treated and intolerant to ibrutinib and/or acatinib
| Abstract Only Summary | Mazyar Shadman, MD, University of Washington, Seattle
| |
| e19507 | Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): long-term follow-up efficacy and safety results from a phase 2 study A one hundred Chak ® clinical study (BGB-A317) for the treatment of relapsed / refractory (R / R) classical Hodgkin lymphoma (cHL) in patients with long-term follow-up of 2 efficacy and safety results | Abstract Only Summary |
